Economic impact of dengue illness in the Americas

Donald S Shepard, Laurent Coudeville, Yara A Halasa, Betzana Zambrano, Gustavo H Dayan, Donald S Shepard, Laurent Coudeville, Yara A Halasa, Betzana Zambrano, Gustavo H Dayan

Abstract

The growing burden of dengue in endemic countries and outbreaks in previously unaffected countries stress the need to assess the economic impact of this disease. This paper synthesizes existing studies to calculate the economic burden of dengue illness in the Americas from a societal perspective. Major data sources include national case reporting data from 2000 to 2007, prospective cost of illness studies, and analyses quantifying underreporting in national routine surveillance systems. Dengue illness in the Americas was estimated to cost $2.1 billion per year on average (in 2010 US dollars), with a range of $1-4 billion in sensitivity analyses and substantial year to year variation. The results highlight the substantial economic burden from dengue in the Americas. The burden for dengue exceeds that from other viral illnesses, such as human papillomavirus (HPV) or rotavirus. Because this study does not include some components (e.g., vector control), it may still underestimate total economic consequences of dengue.

Figures

Figure 1.
Figure 1.
Number of dengue reported cases in the Americas from 2000 to 2007.
Figure 2.
Figure 2.
Method used for estimating cost of non-fatal dengue cases in all American countries.
Figure 3.
Figure 3.
Annual economic burden in the Americas from 2000 to 2007 (in 2010 US$).
Figure 4.
Figure 4.
Variation of total dengue costs according to parameters included in the sensitivity analysis.

References

    1. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11:480–496.
    1. Ooi EE, Gubler DJ. Global spread of epidemic dengue: the influence of environmental change. Future Virol. 2009;4:571–580.
    1. Halstead SB. Dengue. Lancet. 2007;370:1644–1652.
    1. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, Kongsin S, Jiamton S, Garrido F, Montoya R, Armien B, Huy R, Castillo L, Caram M, Sah BK, Sughayyar R, Tyo KR, Halstead SB. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg. 2009;80:846–855.
    1. World Health Organization (WHO) Weekly Epidemiological Record. 2002. Available at. Accessed September 7, 2010.
    1. Gubler DJ. The emergence of epidemic dengue fever and dengue hemorrhagic fever in the Americas: a case of failed public health policy. Rev Panam Salud Publica. 2005;17:221–224.
    1. Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006;12:887–893.
    1. Rigau-Pérez JG, Gubler DJ. Is there an inapparent dengue explosion? Author's reply. Lancet. 1999;353:1101.
    1. Torres JR, Castro J. The health and economic impact of dengue in Latin America. Cad Saúde Pública. 2007;23((Suppl 1)):S23–S31.
    1. Singhasivanon P, Jacobson J. Foreword. J Clin Virol. 2009;46:S1–S2.
    1. Pediatric Dengue Vaccine Initiative (PDVI) PDVI News No. 1, PDVI diagnostic programs. 2006. Available at. Accessed November 17, 2010.
    1. Diaz FJ, Black WC, Farfa'n-Ale JA, Lorono-Pino MA, Olson KE, Beaty BJ. Dengue virus circulation and evolution in Mexico: a phylogenetic perspective. Arch Med Res. 2006;37:760–773.
    1. Pan American Health Organization (PAHO), Communicable Diseases Program Division of Disease Prevention and Control . A Blueprint for Action for the Next Generation: Dengue Prevention and Control. Washington, DC: Pan American Health Organization; 1999. PAHO/HCP/HCT/136/99.
    1. Tapia-Conyer R, Mendez-Galvan JF, Gallardo-Rincon H. The growing burden of dengue in Latin America. J Clin Virol. 2009;46((Suppl 2)):S3–S6.
    1. Pan American Health Organization . Dengue and Dengue Hemorrhagic Fever in the Americas: Guidelines for Prevention and Control. Washington, DC: Pan American Health Scientific Organization; 1994. Publication no. 548.
    1. Pan American Health Organization (PAHO) Surveillance: Number of Cases. 2010. Available at. Accessed June 15, 2010.
    1. Ramírez-Zepeda MG, Velasco-Mondragón HE, Ramos C, Peñuelas JE, Maradiaga-Ceceña MA, Murillo-Llanes J, Rivas-Llamas R, Chaín-Castro R. Clinical and epidemiologic characteristics of dengue cases: the experience of a general hospital in Culiacan, Sinaloa, Mexico Revista Panamericana de Salud Pública/Pan. Am J Public Health. 2009;25:16–23.
    1. San Martin JL, Brathwaite O, Zambrano B, Solorzano JO, Bouckenooghe A, Dayan GH, Guzman MG. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg. 2010;82:128–135.
    1. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008;2:e300.
    1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10:100–103.
    1. Ooi EE, Gubler DJ, Nam VS. Dengue Research Needs Related to Surveillance and Emergency Response. Report of the Scientific Working Group Meeting on Dengue. 2007. Available at. Accessed June 7, 2010.
    1. Ramos MM, Mohammed H, Zielinski-Gutierrez E, Hayden MH, Lopez JL, Fournier M, Trujillo AR, Burton R, Brunkard JM, Anaya-Lopez L, Banicki AA, Morales PK, Smith B, Munoz JL, Waterman SH. Epidemic dengue and dengue hemorrhagic fever at the Texas-Mexico border: results of a household-based seroepidemiologic survey, December 2005. Am J Trop Med Hyg. 2008;78:364–369.
    1. Reiter P, Lathrop S, Bunning M, Biggerstaff B, Singer D, Tiwari T, Baber L, Amador M, Thirion J, Hayes J, Seca C, Mendez J, Ramirez B, Robinson J, Rawlings J, Vorndam V, Waterman S, Gubler D, Clark G, Hayes E. Texas lifestyle limits transmission of dengue virus. Emerg Infect Dis. 2003;9:86–89.
    1. Cuddehe M. Mexico fights rise in dengue fever. Lancet. 2009;374:602.
    1. Tomashek KM, Rivera A, Munoz-Jordan JL, Hunsperger E, Santiago L, Padro O, Garcia E, Sun W. Description of a large island-wide outbreak of dengue in Puerto Rico, 2007. Am J Trop Med Hyg. 2009;81:467–474.
    1. Anez G, Balza R, Valero N, Larreal Y. Economic impact of dengue and dengue hemorrhagic fever in the State of Zulia, Venezuela, 1997–2003. Rev Panam Salud Publica. 2006;19:314–320.
    1. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg. 2008;79:364–371.
    1. Guzman MG, Triana C, Bravo J, Kouri G. The estimation of the economic damages caused as a consequence of the epidemic of hemorrhagic dengue in Cuba in 1981. Rev Cubana Med Trop. 1992;44:13–17.
    1. McConnell KJ, Gubler DJ. Guidelines on the cost-effectiveness of larval control programs to reduce dengue transmission in Puerto Rico. Rev Panam Salud Publica. 2003;14:9–16.
    1. Orellano PW, Pedroni E. Cost-benefit analysis of vector control in areas of potential dengue transmission. Rev Panam Salud Publica. 2008;24:113–119.
    1. Valdes LG, Mizhrahi JV, Guzman MG. Economic impact of dengue 2 epidemic in Santiago de Cuba, 1997. Rev Cubana Med Trop. 2002;54:220–227.
    1. Von Allmen SD, Lopez-Correa RH, Woodall JP, Morens DM, Chiriboga J, Casta-Velez A. Epidemic dengue fever in Puerto Rico, 1977: a cost analysis. Am J Trop Med Hyg. 1979;28:1040–1044.
    1. Clark DV, Mammen MP, Jr, Nisalak A, Puthimethee V, Endy TP. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg. 2005;72:786–791.
    1. Endy T, Yoon I-K, Mammen M. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol. 2010;338:1–13.
    1. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ. Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984–1994. Am J Trop Med Hyg. 1998;59:265–271.
    1. Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health. 2010;10:253.
    1. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26:4080–4093.
    1. Sinha A, Constenla D, Valencia JE, O'Loughlin R, Gomez E, de la Hoz F, Valenzuela MT, de Quadros CA. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publica. 2008;24:304–313.
    1. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ. 2005;83:360–368.
    1. Suaya JA, Shepard DS, Beatty M, Farrar J. Preedy VR, Watson RR. Handbook of Disease Burdens and Quality of Life Measures. New York: Springer; 2010. pp. 1263–1279. (Disease burden of dengue fever and dengue hemorrhagic fever).
    1. Dechant EJ, Rigau-Pérez JG. Hospitalizations for suspected dengue in Puerto Rico, 1991–1995: estimation by capture-recapture methods. The Puerto Rico Association of Epidemiologists. Am J Trop Med Hyg. 1999;61:574–578.
    1. Duarte HH, Franca EB. Data quality of dengue epidemiological surveillance in Belo Horizonte, Southeastern Brazil. Rev Saude Publica. 2006;40:134–142.
    1. Rigau-Perez JG. Surveillance for an emerging disease: dengue hemorrhagic fever in Puerto Rico, 1988–1997. Puerto Rico Association of Epidemiologists. P R Health Sci J. 1999;18:337–345.
    1. Standish K, Kuan G, Aviles W, Balmaseda A, Harris E. High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. PLoS Negl Trop Dis. 2010;4:e633.
    1. Luz PM, Grinsztejn B, Galvani AP. Disability adjusted life years lost to dengue in Brazil. Trop Med Int Health. 2009;14:237–246.
    1. Shepard D. Aggregate economic cost of dengue in Puerto Rico. Proceedings of the 58th Annual Meeting of the American Society of Tropical Medicine and Hygiene. Washington, DC: 2009. November 18–22.
    1. Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Marti SG. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics. 2009;27:919–929.
    1. Goeree R, Burke N, O'Reilly D, Manca A, Blackhouse G, Tarride JE. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin. 2007;23:671–682.
    1. International Monetary Fund World Economic Outlook Database. 2009. Available at. Accessed September 7, 2010.
    1. World Health Organization (WHO) CHOosing Interventions that are Cost Effective (WHO-CHOICE), Country-Specific Costs. 2010. Available at. Accessed June 15, 2010.
    1. World Health Organization (WHO) WHO Guide for Standardization of Economic Evaluations of Immunization Programmes: Immunizations, Vaccines, and Biologicals. 2008. Available at. Accessed June 15, 2010.
    1. World Health Organization (WHO) Life Tables for WHO Member States. 2010. Available at. Accessed June 15, 2010.
    1. World Health Organization The Global Burden of Disease: 2004 Update. 2008. Available at. Accessed June 15, 2010.
    1. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5:157–177.
    1. US Census Bureau International Database (IDB) 2010. Available at. Accessed April 25, 2010.
    1. Gubler D. How effectively is epidemiological surveillance used for dengue programme planning and epidemic response? Dengue Bulletin. 2002;26:96–106.
    1. Ramos MM, Argüello DF, Luxemburger C, Quiñones L, Muñoz JL, Beatty M, Lang J, Tomashek KM. Epidemiological and clinical observations on patients with dengue in Puerto Rico: results from the first year of enhanced surveillance—June 2005–May 2006. Am J Trop Med Hyg. 2008;79:123–127.
    1. World Health Organization (WHO) CHOosing Interventions that are Cost Effective (WHO-CHOICE) 2006. Available at. Accessed September 7, 2010.
    1. Kongsin S, Jiamton S, Suaya JA, Vasanawathana S, Sirisuvan P, Shepard DS. Cost of Dengue in Thailand. Bangkok. Thailand: Mahidol University School of Public Health; 2010.
    1. Mavalankar DV, Puwar TI, Murtola TM, Vasan SS. Quantifying the Impact of Chikungunya and Dengue on Tourism Revenues. 2009. IIMA Working Paper No. 2009-02-03. Available at. Accessed June 23, 2010.
    1. de Epidemiología D, Estratégico A. Ministerio del Poder Popular para la Salud, Gobierno Bolivariano de Venezuela, Boletín Epidemiológico Semanal (year 56, weeks 1–52) 2007. Available at. Accessed May 20, 2010.
    1. Pan American Health Organization (PAHO) Number of Reported Cases of Dengue and Dengue Hemorrhagic Fever (DHF) in the Americas, by Country (years 1995–2009) 2010. Available at. Accessed April 25, 2010.
    1. Camacho T, de la Hoz F, Cardenas V, Sanchez C, de Calderon L, Perez L, Bermudez A. Incomplete surveillance of a dengue-2 epidemic in Ibague, Colombia, 1995-1997. Biomedica. 2004;24:174–182.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner